Neumora plans clinical trials, data readouts through 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
Big Stock Moves on NLRP3 Competitive Landscape News; Positive Read-throughs for Neumora Therapeutics (NMRA) - Mizuho
January 7, 2026 1:20 PM ESTMizuho analyst Graig Suvannavejh reiterated an Outperform rating and $6.00 price target on Neumora Therapeutics (NASDAQ: NMRA)
The analyst comets "NMRA shares are +25-30 intraday (vs. +3% XBI) and +50% (vs. +5% XBI) over the past two trading sessions, following we believe recent media... More
